J Diego Baldo

Suggest Changes
Learn More
BACKGROUND The development of vaccines against pandemic influenza viruses for use in children is a public health priority. METHODS In this phase II, randomized, open study, the immunogenicity and(More)
BACKGROUND An AS03-adjuvanted H5N1 influenza vaccine elicited broad and persistent immune responses with an acceptable safety profile up to 6 months following the first vaccination in children aged(More)
  • 1